FDA Clears AI Tool to Predict Breast Cancer Recurrence Before Surgery

Key points

• TumorSight Risk uses AI to analyze breast MRIs and clinical data to estimate recurrence risk over five to ten years.
• The tool classifies patients as low, intermediate, or high risk, with high-risk patients facing over three times the recurrence risk of low-risk patients.
• SimBioSys is working with Medicare, Medicaid, and private insurers to secure coverage for the test.
• The technology is already being used in hospitals and cancer centers nationwide to inform treatment decisions.
• A study of 2,129 women showed 95.5% of low-risk patients remained cancer-free after five years, compared to 89.6% of high-risk patients.

Background

Recent advancements in AI for breast cancer include tools that predict drug responses and detect cancer years earlier. While some AI mammogram tools are moving to direct consumer markets, others remain in research phases. The FDA clearance of TumorSight Risk adds to the growing list of AI tools aimed at improving breast cancer outcomes.

How outlets are covering it

ABC News highlights the FDA clearance and the potential for TumorSight Risk to provide earlier and more personalized treatment decisions. CBS News emphasizes the broader impact of AI in breast cancer detection, noting that AI can help close racial and socioeconomic gaps in diagnosis and treatment. Bioengineer.org raises concerns about the diversity of datasets used in AI development, warning that high benchmark results may not translate to broad clinical performance. OncLive focuses on the specific FDA clearance of TumorSight Risk for hormone receptor-positive, HER2-negative breast cancer.

Why it matters

The FDA clearance of TumorSight Risk marks a significant step in the integration of AI into breast cancer treatment. By providing earlier and more personalized risk assessments, the tool can help patients and doctors make more informed decisions about treatment options, potentially reducing the need for aggressive treatments and improving outcomes.

What to watch

SimBioSys is working with insurers to secure coverage for TumorSight Risk. The tool is already being used in hospitals and cancer centers nationwide. Future developments may include broader adoption and integration with other AI tools for breast cancer detection and treatment.